27.11.2024 16:52 | AGY | IN BRIEF: Allergy Therapeutics treats first patient in allergy trial | Alliance |
27.11.2024 07:00 | AGY | First Patient Dosed in G308 Paediatric Trial | RNS |
25.11.2024 07:00 | AGY | Submission of MAA for Grass MATA MPL | RNS |
21.11.2024 07:00 | AGY | Notice of 2024 Annual General Meeting | RNS |
06.11.2024 11:22 | AGY | Allergy Therapeutics annual loss narrows thanks to reduced expenses | Alliance |
06.11.2024 07:00 | AGY | Audited Preliminary Results 2024 | RNS |
21.10.2024 07:00 | AGY | Commencement of Phase III Paediatric Trial | RNS |
16.10.2024 10:58 | AGY | Allergy Therapeutics shares surge as enters into secured loan facility | Alliance |
16.10.2024 07:00 | AGY | Update on funding | RNS |
01.10.2024 07:00 | AGY | Update on funding and preliminary results | RNS |
17.09.2024 07:00 | AGY | Progression of patient cohorts in PROTECT Trial | RNS |
27.08.2024 10:46 | AGY, GROC, BELL | AIM WINNERS & LOSERS: Belluscura shares up on expected revenue boost | Alliance |
27.08.2024 09:57 | AGY | Allergy Therapeutics secures cash to see it through September | Alliance |
27.08.2024 07:00 | AGY | Update on funding | RNS |
22.07.2024 16:26 | AGY, MFAI, KDNC | TRADING UPDATES: Croma Security trading well; Fonix to up final payout | Alliance |
22.07.2024 07:01 | AGY | Trading update for the year ended 30 June 2024 | RNS |
22.07.2024 07:00 | AGY | Appointment of Nominated Adviser and Sole Broker | RNS |
04.07.2024 14:22 | AGY | Launch of new Company Long Term Incentive Plan | RNS |
27.06.2024 07:00 | AGY | Appointment of Non-Executive Director | RNS |
10.06.2024 10:32 | AGY, MSMN, AREC | AIM WINNERS & LOSERS: Arecor Therapeutics dives on funding needs | Alliance |
10.06.2024 09:36 | AGY | Allergy Therapeutics welcomes peanut allergy vaccine trial results | Alliance |
10.06.2024 07:00 | AGY | Progression of patient cohorts in PROTECT Trial | RNS |
03.06.2024 07:00 | AGY | Successful meetings with Paul Ehrlich Institut | RNS |
31.05.2024 07:00 | AGY | Allergy Therapeutics presents findings at EAACI | Reach |
07.05.2024 20:22 | EMH, KDNC, ECR | TRADING UPDATES: Abingdon Health buys IVDeology Holdings | Alliance |
07.05.2024 07:00 | AGY | Further detail from G306 Phase III field trial | RNS |
03.04.2024 07:00 | AGY | Director Resignation | RNS |
27.03.2024 16:13 | LPA, LDSG, SOLI | EARNINGS AND TRADING: Solid State ups outlook; Quartix trading in line | Alliance |
27.03.2024 11:02 | AGY, NBB | AIM WINNERS & LOSERS: Norman Broadbent profit swing on rising revenue | Alliance |
27.03.2024 07:00 | AGY | Update on funding | RNS |
27.03.2024 07:00 | AGY | Interim Results for six months ended 31 Dec 2023 | RNS |
12.03.2024 14:06 | AGY | Allergy Therapeutics starts dosing patients in peanut allergy trial | Alliance |
12.03.2024 08:59 | AGY | VLP Peanut PROTECT Trial Update | RNS |
12.03.2024 07:00 | AGY | VLP Peanut PROTECT Trial Update | Reach |
11.03.2024 07:00 | AGY | Appointment of Shaun Furlong to Board of Directors | RNS |
08.03.2024 13:49 | AGY | Result of AGM | RNS |
01.03.2024 15:49 | SCP, NEO, TORO | UK shareholder meetings calendar - next 7 days | Alliance |
14.02.2024 10:22 | AGY | Allergy Therapeutics forecasts revenue drop but trials going well | Alliance |
14.02.2024 07:00 | AGY | Half-Year Trading Update 2024 | RNS |
09.02.2024 15:07 | AGY | Notice of 2023 Annual General Meeting | RNS |
05.02.2024 14:09 | APH, AGY, SCLP | TRADING UPDATES: Alliance Pharma appoints chair; FireAngel sales down | Alliance |
30.01.2024 10:38 | AGY | Allergy Therapeutics resumes trading on AIM; annual revenue plunges | Alliance |
30.01.2024 07:30 | AGY | Restoration - Allergy Therapeutics plc | RNS |
30.01.2024 07:00 | AGY | Publication of Annual Report and Accounts 2023 | RNS |
04.01.2024 12:29 | AGY | Total Voting Rights | RNS |
02.01.2024 07:30 | AGY | Suspension - Allergy Therapeutics plc | RNS |
27.12.2023 14:17 | AGY | IN BRIEF: Allergy Therapeutics amends facility, plans warrant issue | Alliance |
27.12.2023 12:01 | AGY | Amendment to existing Facility Agreement | RNS |
15.12.2023 21:09 | DCTA, AGY, BRH | EARNINGS AND TRADING: Redx full year revenue tumbles; loss widens | Alliance |
15.12.2023 12:48 | AGY | Annual Report and Accounts Delayed | RNS |
13.12.2023 16:54 | AGY | PDMR dealing and Total Voting Rights | RNS |
13.12.2023 10:11 | AGY | Allergy Therapeutics shares jump as hails grass allergy jab data | Alliance |
13.12.2023 09:55 | FME, AGY | AIM WINNERS & LOSERS: Impellam climbs on GBP483 million takeover offer | Alliance |
13.12.2023 07:00 | AGY | G306 Phase III trial meets key endpoints | RNS |
11.12.2023 10:45 | AGY, DKL, SNX | AIM WINNERS & LOSERS: Synectics to beat forecast; Dekel shares jump | Alliance |
11.12.2023 10:40 | AGY | IN BRIEF: Allergy Therapeutics stock falls on lower sales outlook | Alliance |
11.12.2023 07:00 | AGY | Update on funding | RNS |
01.12.2023 07:00 | AGY | Total Voting Rights | RNS |
28.11.2023 15:03 | AGY | Holding(s) in Company | RNS |
14.11.2023 11:56 | AGY | Allergy Therapeutics says allergy therapy trial meets primary endpoint | Alliance |
14.11.2023 10:59 | RENX, AGY, DPP | AIM WINNERS & LOSERS: Renalytix revenue halves; DP Poland trades well | Alliance |
14.11.2023 07:00 | AGY | G306 Grass Phase III trial meets primary endpoint | RNS |
10.11.2023 14:39 | AGY | Form 8.5 (EPT/RI) | RNS |
10.11.2023 13:22 | AGY | Director/PCA Dealing | RNS |
10.11.2023 13:11 | AGY | Holding(s) in Company | RNS |
10.11.2023 07:00 | AGY | Offer Closure | RNS |
09.11.2023 10:48 | AGY | Exercise of Options and Total Voting Rights | RNS |
09.11.2023 09:24 | AGY | Form 8.5 (EPT/RI) | RNS |
09.11.2023 09:15 | AGY | Form 8.5 (EPT/NON-RI) | RNS |
08.11.2023 10:45 | AGY | Form 8.5 (EPT/RI) | RNS |
07.11.2023 11:10 | AGY | Form 8.5 (EPT/RI) | RNS |
06.11.2023 12:33 | AGY | IN BRIEF: Allergy Therapeutics extends cash runway until end of 2023 | Alliance |
06.11.2023 09:33 | AGY | Form 8.5 (EPT/RI) | RNS |
06.11.2023 07:00 | AGY | Update on funding | RNS |
03.11.2023 09:31 | AGY | Form 8.5 (EPT/RI) | RNS |